Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Division of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester, UK.
Eur J Hum Genet. 2022 May;30(5):520-531. doi: 10.1038/s41431-022-01054-5. Epub 2022 Mar 8.
Genetic screening can be hugely beneficial, yet its expansion poses clinical and ethical challenges due to results of uncertain clinical relevance (such as 'cystic fibrosis screen positive, inconclusive diagnosis'/CFSPID). This review systematically identifies, appraises, and synthesises the qualitative research on experiences of receiving results of uncertain clinical relevance from population genetic screening. Eight databases were systematically searched for original qualitative research using the SPIDER framework, and checked against inclusion criteria by the research team and an independent researcher. Nine papers were included (from USA, Canada, UK, New Zealand). PRISMA, ENTREQ, and EMERGE guidance were used to report. Quality was appraised using criteria for qualitative research. All papers focused on parental responses to uncertain results from newborn screening. Data were synthesised using meta-ethnography and first- and second-order constructs. Findings suggest that results of uncertain clinical relevance are often experienced in the same way as a 'full-blown' diagnosis. This has significant emotional and behavioural impact, for example adoption of lifestyle-altering disease-focused behaviours. Analysis suggests this may be due to the results not fitting a common medical model, leading recipients to interpret the significance of the result maladaptively. Findings suggest scope for professionals to negotiate and reframe uncertain screening results. Clearer initial communication is needed to reassure recipients there is no immediate severe health risk from these types of results. Public understanding of an appropriate medical model, that accounts for uncertain genetic screening results in a non-threatening way, may be key to maximising the benefits of genomic medicine and minimising potential psychological harm.
遗传筛查可能非常有益,但由于不确定临床相关性的结果(例如“囊性纤维化筛查阳性,不确定诊断”/CFSPID),其扩展带来了临床和伦理挑战。本综述系统地识别、评估和综合了有关人群遗传筛查不确定临床相关性结果的经验的定性研究。使用 SPIDER 框架对 8 个数据库进行了系统搜索,以寻找原始定性研究,并由研究团队和独立研究人员对照纳入标准进行检查。纳入了 9 篇论文(来自美国、加拿大、英国和新西兰)。使用 PRISMA、ENTREQ 和 EMERGE 指南进行报告。使用定性研究的标准评估质量。所有论文都集中在父母对新生儿筛查不确定结果的反应上。使用元民族志和一阶和二阶结构对数据进行综合。研究结果表明,不确定临床相关性的结果通常与“全面”诊断的方式相同。这会产生重大的情感和行为影响,例如采用改变生活方式的以疾病为中心的行为。分析表明,这可能是由于结果不符合常见的医学模型,导致接受者不适应地解释结果的意义。研究结果表明,专业人员有协商和重新构建不确定筛查结果的空间。需要更清晰的初步沟通,以向接受者保证这些类型的结果不会立即带来严重的健康风险。公众对适当的医学模型的理解,以一种非威胁的方式解释不确定的遗传筛查结果,可能是最大限度地发挥基因组医学的益处和最小化潜在心理伤害的关键。